Ifosfamide
Showing 1 - 25 of 560
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue Trial in Saint Louis (ADI PEG20, Ifosfamide, Radiotherapy)
Not yet recruiting
- Soft Tissue Sarcoma
- +2 more
- ADI PEG20
- +3 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 2, 2023
Soft Tissue Sarcoma Trial in Guangzhou (Sintilimab plus chemo)
Recruiting
- Soft Tissue Sarcoma
- Sintilimab plus chemotherapy
-
Guangzhou, Guangdong, ChinaXing Zhang
Sep 4, 2022
Penile Cancer Trial in Guangzhou (Albumin-Bound Paclitaxel, Ifosfamide, Cisplatin)
Completed
- Penile Cancer
- Albumin-Bound Paclitaxel
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 8, 2022
Pediatric Germ Cell Tumor Trial in Seoul (TIP treatment (paclitaxel/ifosfamide/cisplatin))
Recruiting
- Pediatric Germ Cell Tumor
- TIP treatment (paclitaxel/ifosfamide/cisplatin)
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Jul 8, 2022
Effect of Drug, Toxicity, Drug, Secondary Resistance Trial in Beijing (Apatinib Mesylate, ifosfamide and etoposide)
Completed
- Effect of Drug
- +2 more
- Apatinib Mesylate
- ifosfamide and etoposide
-
Beijing, Beijing, ChinaPeking University People's Hospital
Mar 12, 2022
DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)
Recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Glofitamab
- +6 more
-
Pembroke Pines, Florida
- +3 more
Jan 23, 2023
Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)
Recruiting
- Classic Hodgkin's Lymphoma
- Sintilimab
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma Trial in Santa Monica (aldoxorubicin, ifosfamide)
Completed
- Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
- aldoxorubicin
- ifosfamide
-
Santa Monica, CaliforniaSarcoma Oncology Center
Jan 27, 2022
Soft Tissue Sarcoma Trial in Guangzhou (Apatinib Mesylate, doxorubicin, ifosfamide)
Recruiting
- Soft Tissue Sarcoma
- Apatinib Mesylate, doxorubicin, ifosfamide
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Nov 15, 2021
Non-Hodgkin's Lymphoma Trial in New York (Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin,
Completed
- Non-Hodgkin's Lymphoma
- Etoposide, carboplatin, ifosfamide
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 23, 2022
Neuroblastoma, Pediatric Cancer Trial in New York (Cyclophosphamide, Topotecan, Vincristine)
Recruiting
- Neuroblastoma
- Pediatric Cancer
- Cyclophosphamide
- +7 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 11, 2023
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Carboplatin
- +4 more
-
Duarte, California
- +3 more
Oct 24, 2022
Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)
Recruiting
- Lymphoma
- Radiation Therapy
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 9, 2022
Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)
Not yet recruiting
- Mature B-Cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
- (no location specified)
Sep 6, 2022
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023
Non-metastatic Soft-tissue Sarcoma, Resectable Trial in France (Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the
Recruiting
- Non-metastatic Soft-tissue Sarcoma
- Resectable
- Doxorubicin
- +2 more
-
Bordeaux, France
- +9 more
Jul 27, 2022
Hodgkin Lymphoma Trial in Saint Petersburg, Irkutsk (Nivolumab, Ifosfamide, Carboplatin)
Recruiting
- Hodgkin Lymphoma
- Nivolumab
- +3 more
-
Saint Petersburg, Pesochny, Russian Federation
- +2 more
Jul 19, 2021
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,
Terminated
- Diffuse Large B Cell Lymphoma
- +3 more
- Acalabrutinib
- +4 more
-
Miami, FloridaUniversity of Miami
Aug 23, 2022
Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)
Active, not recruiting
- Diffuse Large B-cell-lymphoma
- Venetoclax
- +4 more
-
Saint Louis, Missouri
- +2 more
Nov 14, 2022